Patents by Inventor Harvey Cantor

Harvey Cantor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells
    Patent number: 12202904
    Abstract: Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12R? activity and/or IL-12R? expression.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: January 21, 2025
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jessica M. Sido
  • COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCER
    Publication number: 20240415919
    Abstract: Aspects of the invention are drawn to compositions and methods for modulating CD8 Treg mobilization in the treatment of autoimmune disorders, rejection of transplanted organs and cancer.
    Type: Application
    Filed: August 30, 2022
    Publication date: December 19, 2024
    Inventors: Harvey CANTOR, Hye-Jung KIM, Hidetoshi NAKAGAWA, John Yongjoon CHOI, Jamil AZZI
  • IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS
    Publication number: 20230406944
    Abstract: Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12RP activity and/or IL-12RP expression.
    Type: Application
    Filed: February 27, 2023
    Publication date: December 21, 2023
    Inventors: Harvey Cantor, Hye-Jung Kim, Jessica M. Sido
  • TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
    Publication number: 20230302106
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Application
    Filed: February 27, 2023
    Publication date: September 28, 2023
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells
    Patent number: 11591403
    Abstract: Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12RP activity and/or IL-12RP expression.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: February 28, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jessica M. Sido
  • Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
    Patent number: 11590213
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 28, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
    Patent number: 11371989
    Abstract: Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 28, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Harvey Cantor, Jianmei Wu Leavenworth
  • TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
    Publication number: 20210268081
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Application
    Filed: December 18, 2019
    Publication date: September 2, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS
    Publication number: 20210040220
    Abstract: Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12RP activity and/or IL-12RP expression.
    Type: Application
    Filed: May 2, 2018
    Publication date: February 11, 2021
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jessica M. Sido
  • TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
    Publication number: 20200297828
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Application
    Filed: December 18, 2019
    Publication date: September 24, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • Discovery of regulatory T cells programmed to suppress an immune response
    Patent number: 10596195
    Abstract: A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: March 24, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Linrong Lu
  • IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS
    Publication number: 20200055945
    Abstract: Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12RP activity and/or IL-12RP expression.
    Type: Application
    Filed: May 2, 2018
    Publication date: February 20, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jessica M. Sido
  • Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
    Patent number: 10548957
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: February 4, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • METHODS TO INDUCE CONVERSION OF REGULATORY T CELLS INTO EFFECTOR T CELLS FOR CANCER IMMUNOTHERAPY
    Publication number: 20190192565
    Abstract: Provided by the disclosure are methods for modulating differentiation of regulatory T cells (e.g., CD4+ or CD8+ regulatory T cells). In some embodiments, methods include contacting regulatory T cells with an agent that decreases Helios activity and/or Helios expression.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 27, 2019
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim
  • INTRACELLULAR OSTEOPONTIN REGULATES THE LINEAGE COMMITMENT OF LYMPHOID SUBSETS
    Publication number: 20190178884
    Abstract: Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.
    Type: Application
    Filed: November 19, 2018
    Publication date: June 13, 2019
    Inventors: Harvey Cantor, Jianmei Wu Leavenworth
  • INTRACELLULAR OSTEOPONTIN REGULATES THE LINEAGE COMMITMENT OF LYMPHOID SUBSETS
    Publication number: 20170269076
    Abstract: Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.
    Type: Application
    Filed: August 27, 2015
    Publication date: September 21, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Jianmei Wu Leavenworth
  • DISCOVERY OF REGULATORY T CELLS PROGRAMMED TO SUPPRESS AN IMMUNE RESPONSE
    Publication number: 20170224732
    Abstract: A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided.
    Type: Application
    Filed: January 13, 2017
    Publication date: August 10, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Linrong Lu
  • TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS
    Publication number: 20150250862
    Abstract: Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 10, 2015
    Inventors: Harvey Cantor, Hye-Jung Kim, Jianmei Wu Leavenworth
  • DISCOVERY OF REGULATORY T CELLS PROGRAMMED TO SUPPRESS AN IMMUNE RESPONSE
    Publication number: 20130302276
    Abstract: A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided.
    Type: Application
    Filed: October 18, 2011
    Publication date: November 14, 2013
    Applicant: DANA-FARBER CANCER INSITUTE INC.,
    Inventors: Harvey Cantor, Hye-Jung Kim, Linrong Lu
  • Regulation of mink in thymocytes and T lymphocytes
    Patent number: 8197817
    Abstract: The invention relates to compositions and methods used to assess and alter the expression and activity of MINK in cells of the immune system, particularly thymocytes and T lymphocytes. The methods and compositions are used in a variety of clinical applications including vaccination, treatment of cancer, infectious disease, allergy, and transplantation. Screening methods are provided to identify inhibitors of MINK and susceptibility to effects of under- or over-expression of MINK.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: June 12, 2012
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Nami McCarty